登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，3月19日，Use of antiviral drugs to reduce COVID-19 transmission》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-20

  • Use of antiviral drugs to reduce COVID-19 transmission

    Oriol Mitjà

    Bonaventura Clotet

    Open AccessPublished:March 19, 2020DOI:https://doi.org/10.1016/S2214-109X(20)30114-5

    As the coronavirus disease 2019 (COVID-19) spreads, efforts are being made to reduce transmission via standard public health interventions based on isolation of cases and tracing of contacts. In their modelling study, Joel Hellewell and colleagues1 predict that such a strategy could contribute to reducing the overall size of an outbreak, but will still be insufficient to achieve outbreak control of COVID-19 when the basic reproduction number (R0) is higher than 1·5 or the proportion of contacts traced is lower than 80%.

  • 原文来源：https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30114-5/fulltext
8浏览量
原文链接
相关报告

  • 《LANCET，2月27日，COVID-19: combining antiviral and anti-inflammatory treatments》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-28
    • COVID-19: combining antiviral and anti-inflammatory treatments Justin Stebbing, Anne Phelan, Ivan Griffin, Catherine Tucker, Olly Oechsle, Dan Smith, et al. Published:February 27, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30132-8 Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for SARS, viral load is not correlated with the worsening of symptoms.1, 2 In our previous Correspondence to The Lancet,3 we described how BenevolentAI's proprietary artificial intelligence (AI)-derived knowledge graph,4 queried by a suite of algorithms, enabled identification of a target and a potential therapeutic against SARS coronavirus 2 (SARS-CoV-2; the causative organism in COVID-19). We identified a group of approved drugs that could inhibit clathrin-mediated endocytosis and thereby inhibit viral infection of cells (appendix). The drug targets are members of the numb-associated kinase (NAK) family—including AAK1 and GAK—the inhibition of which has been shown to reduce viral infection in vitro.5, 6 Baricitinib was identified as a NAK inhibitor, with a particularly high affinity for AAK1, a pivotal regulator of clathrin-mediated endocytosis. We suggested that this drug could be of use in countering SARS-CoV-2 infections, subject to appropriate clinical testing.
    119浏览量
    原文链接

  • 《LANCET，4月3日，Baricitinib for COVID-19: a suitable treatment? – Authors' reply》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-04
    • Baricitinib for COVID-19: a suitable treatment? – Authors' reply Peter J Richardson，Mario Corbellino，Justin Stebbing Published:April 03, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30270-X We thank Ennio Favalli and colleagues for their Correspondence regarding our suggestion to use baricitinib for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.1, 2 We also appreciate their recognition that inhibition of numb-associated kinase enzymes could indeed be beneficial in preventing virus infectivity via inhibition of clathrin-mediated endocytosis. We welcome the opportunity to more fully explain the possible use of baricitinib in the current pandemic. Indeed, we accept that using a JAK1 and JAK2 inhibitor to treat a viral disease might appear illogical given that the antiviral effects of interferons are largely mediated by the JAK–STAT signalling pathway. However, the administration of pegylated-interferon has not had the beneficial antiviral effects originally hoped for,4 and clinical trials with interferons have yielded inconsistent results, with pathogenic effects of interferons being observed in some viral infections.
    93浏览量
    原文链接